VERACITY® is a new-generation non-invasive prenatal test (NIPT) that accurately screens for specific fetal genetic conditions as early as from the 10th week of pregnancy using a maternal blood sample.
It measures cell-free fetal DNA circulating with the mother’s DNA
and identifies genetic abnormalities with high precision.
Safety
A non-invasive test with no risk for the mother or the baby.
Accuracy
More than 99% detection accuracy for the conditions tested.
Simplicity
Only a simple maternal blood sample is required.
Speed
Results available within 15 working days from sample receipt at the laboratory.
Scientific reliability
A non-invasive test with no risk for the mother or the baby.
During pregnancy, small fragments of fetal DNA are naturally released from the placenta and circulate in the mother’s bloodstream. VERACITY® analyzes this cell-free fetal DNA (cfDNA) using advanced genomic technologies, without interfering with the pregnancy.
Blood sampling is performed at our diagnostic center (or at home by appointment). Samples are then sent from our laboratory to the specialized laboratories of Medicover Genetics for analysis.Results are typically available within 10 working days from sample receipt.
VERACITY® is suitable for all pregnant women, regardless of age
or risk category.
It can also be performed in pregnancies achieved through:
• IVF
• egg or sperm donation
• surrogacy
In clinical practice, prenatal genetic screening is often recommended for women over the age of 35 or in cases of family history, while it can be performed in any pregnancy, regardless
of age.
Autosomal
Aneuploidies
Down syndrome (Trisomy 21)
Edwards syndrome (Trisomy 18)
Patau syndrome (Trisomy 13)
Sex Chromosome Aneuploidies
Turner syndrome (45,X)
Triple X syndrome (47,XXX)
Klinefelter syndrome (47,XXY)
Jacobs syndrome (47,XYY)
XXYY syndrome
Microdeletions
DiGeorge syndrome (22q11.2)
1p36 deletion syndrome
Smith–Magenis syndrome (17p11.2)
Wolf–Hirschhorn syndrome (4p16.3)
| KARYOTYPE | NUMBER | FOLLOW-UP | CONFIRMED | SPECIFICITY / SENSITIVITY | NPV / PPV |
|---|---|---|---|---|---|
| Normal | 12211 | 12211 | 12211 | >99.9% | 100% |
| Trisomy 21 | 144 | 45 | 45 | 100% | 100% |
| Trisomy 18 | 30 | 11 | 11 | 100% | 100% |
| Trisomy 13 | 16 | 7 | 5 | 100% | 71% |
| SCAs† | 45 | 16 | 13 | 100% | 81% |
Clinical Performance
& Technology
behind VERACITY®
VERACITY is based on Target Capture Enrichment technology, allowing:
• repeated analysis of clinically relevant genomic regions
• reliable fetal fraction measurement
• high analytical accuracy and reproducibility
Clinical validation studies demonstrate:
• Sensitivity >99%
• Specificity >99%
Learn more about the clinical performance of VERACITY
| Subtype | Number of Samples | Reassessment | Accuracy | Specificity | Negative Predictive Value |
|---|---|---|---|---|---|
| Normal | 10 | 10 | 10 | 99.98% (95% CI: 99.93–99.998%) | 100% (95% CI: 99.96–100%) |
| Karyotype | Number of Samples | Reassessment | Accuracy | Sensitivity | Positive Predictive Value |
|---|---|---|---|---|---|
| Trisomy 21 | 126 | 44 | 44 | 100% (95% CI: 69–100%) | 100% (95% CI: 92–100%) |
| Trisomy 18 | 24 | 10 | 10 | 100% (95% CI: 69–100%) | 100% (95% CI: 69–100%) |
| Trisomy 13 | 16 | 7 | 5 | 100% (95% CI: 48–100%) | 71% (95% CI: 29–96%) |
| Karyotype | Number of Samples | Reassessment | Accuracy | Specificity | Negative Predictive Value |
|---|---|---|---|---|---|
| Normal | 6,2 | 6,2 | 6,2 | 99.95% (95% CI: 99.86–99.99%) | 100% (95% CI: 99.94–100%) |
| Karyotype | Number of Samples | Reassessment | Accuracy | Sensitivity | Positive Predictive Value |
|---|---|---|---|---|---|
| 45,X (Turner) | 16 | 7 | 4 | 100% (95% CI: 40–100%) | 57% (95% CI: 18–90%) |
| 47,XXX | 6 | 2 | 2 | – | – |
| 47,XXY (Klinefelter) | 10 | 4 | 4 | – | – |
| 47,XYY | 3 | 0 | – | – | – |
| 48,XXYY | 1 | 1 | 1 | – | – |
Unique features of
VERACITY®
TARGETED GENOMIC ANALYSIS
VERACITY uses advanced Target Capture Sequencing technology to analyze selected genomic regions associated with aneuploidies. This targeted approach enhances the accuracy and reliability of the test.
HIGH-DEPTH TARGETED SEQUENCING
Hundreds of repeated analyses are performed on selected DNA regions, increasing statistical precision and improving the sensitivity and specificity of the test.
RELIABLE FETAL DNA MEASUREMENT
VERACITY uses advanced bioinformatics algorithms for accurate fetal fraction measurement, strengthening the reliability of the results.
DNA FRAGMENT ANALYSIS
TACS technology enables the analysis of DNA fragment size, improving discrimination between normal and abnormal samples and increasing detection accuracy.
Blood sampling is performed at our diagnostic center or at home by appointment.
Samples are sent from our laboratory to Medicover Genetics for analysis.
Results are delivered to the healthcare provider and/or the patient within 10 working days